Duncker Streett & Co. Inc. Sells 1,380 Shares of Johnson & Johnson $JNJ

Key Points

• Duncker Streett & Co. Inc. reduced its stake in Johnson & Johnson by 8.6%, selling 1,380 shares, bringing its total holdings to 14,716 shares valued at approximately $2,248,000.
• Several brokerages have raised their target prices for Johnson & Johnson, with Citigroup and JPMorgan Chase increasing their targets to $215.00 and $200.00 respectively, indicating a generally positive outlook on the stock.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, with an annual yield of 2.7%, reflecting a solid dividend payout ratio of 55.61%.

Duncker Streett & Co. Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,716 shares of the company's stock after selling 1,380 shares during the quarter. Duncker Streett & Co. Inc.'s holdings in Johnson & Johnson were worth $2,248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Rosenberg Matthew Hamilton grew its stake in shares of Johnson & Johnson by 15.0% during the 2nd quarter. Rosenberg Matthew Hamilton now owns 3,438 shares of the company's stock worth $525,000 after acquiring an additional 449 shares during the period. IFG Advisors LLC grew its stake in shares of Johnson & Johnson by 5.4% during the 2nd quarter. IFG Advisors LLC now owns 4,649 shares of the company's stock worth $710,000 after acquiring an additional 239 shares during the period. Triton Wealth Management PLLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth $438,000. Mitchell Mcleod Pugh & Williams Inc. grew its stake in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 27,465 shares of the company's stock worth $4,195,000 after acquiring an additional 443 shares during the period. Finally, JGP Wealth Management LLC grew its stake in shares of Johnson & Johnson by 1.7% during the 2nd quarter. JGP Wealth Management LLC now owns 42,165 shares of the company's stock worth $6,441,000 after acquiring an additional 719 shares during the period. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. Citigroup raised their target price on Johnson & Johnson from $213.00 to $215.00 and gave the stock a "buy" rating in a research note on Wednesday. JPMorgan Chase & Co. raised their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 16th. Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday. Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $199.59.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $193.27 on Friday. The business's 50-day moving average price is $180.49 and its two-hundred day moving average price is $164.80. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.40. The stock has a market cap of $465.45 billion, a P/E ratio of 18.65, a PEG ratio of 2.26 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.